ASX Company Announcements


The edited text of our announcements are sourced from the Australian Stock Exchange and are delayed by at least 20 minutes. Retrieving the edited text of a company announcement indicates your acceptance of the Conditions.

Cellmid does not take any responsibility in respect of any of the edited text sourced from the Australian Stock Exchange

16/09/2019

 Appendix 4G and Corporate Governance Statement

16/09/2019

 2019 Annual Report to shareholders

 28/08/2019

 FY19 Results Presentation 

 28/08/2019

 Appendix 4E and FY19 Financial Report

 28/08/2019

 FY2019 Financial Results

 22/08/2019

 Patent for Improved Midkine Antibody Allowed in Europe

 06/08/2019

 Cellmid signs distribution agreement for Evolis in South Korea

 01/08/2019

 Appendix 4C Query

 31/07/2019

 Appendix 3B New issue annoucement, application for quotation of additional securities and   agreement

 26/07/2019

 Cellmid Notes to the Appendix 4C

 10/07/2019

 Cellmid Investor Newsletter

 05/07/2019

 ASX Aware Query

 04/07/2019

 Cellmid sets another sales record in Q4 FY2019

 06/06/2019

 Change of Director's Interest Notice 

 28/05/2019

 Cellmid appoints Lyramid CEO to Accelerate Partnering

 28/05/2019

 FY2020 Growth Strategy Update May 2019

 23/05/2019

 Minimum holding buy-back completed

 21/05/2019

 Minimum holding buy-back closed

06/05/2019

 Appendix 3Y - Change of Director's Interest Notice

30/04/2019

 Cellmid's evolis registered in European Union

29/04/2019

 Cellmid notes to the Appendix 4C

18/04/2019

 Repayment of Cellmid loan issued to Director pursuant to employee incentive plan

02/04/2019

 Cellmid Alopecia Patent allowed in Europe

 26/03/2019

 Cellmid Investor Newsletter March 2019

 19/03/2019

 Minimum Holding Share Buy-Back

 21/02/2019

 Appendix 4D, Half Year Accounts and Strategy Update

 07/02/2019

 Significant New Findings Published On MIDKINE

 23/01/2019

 Appendix 4C and Notes to Appendix 4C